Skip to main content

Rosetta Closes $2.5M Private Placement


Rosetta Genomics this week announced that it has entered into a definitive agreement to sell securities to institutional investors in a private placement for aggregate gross proceeds of about $2.5 million.

Specifically, Rosetta will sell 2.5 million ordinary shares at a price of $1.00 per share, and give the purchasers warrants to buy up to 1.25 million ordinary shares at an exercise price of $1.30 per share and warrants to purchase up to 625,000 ordinary shares at an exercise price of $0.01 per share.

Rosetta said it will use the proceeds of the private placement for working capital purposes.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.